Your browser doesn't support javascript.
loading
Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study.
Fassnacht, Martin; Berruti, Alfredo; Baudin, Eric; Demeure, Michael J; Gilbert, Jill; Haak, Harm; Kroiss, Matthias; Quinn, David I; Hesseltine, Elizabeth; Ronchi, Cristina L; Terzolo, Massimo; Choueiri, Toni K; Poondru, Srinivasu; Fleege, Tanya; Rorig, Ramona; Chen, Jihong; Stephens, Andrew W; Worden, Francis; Hammer, Gary D.
  • Fassnacht M; Department of Internal Medicine I, Endocrine and Diabetes Unit, University Hospital, University of Würzburg, Würzburg, Germany; Comprehensive Cancer Center Mainfranken, University of Würzburg, Würzburg, Germany; Central Laboratory, Research Unit, University Hospital Würzburg, Würzburg, Germany.
  • Berruti A; Department of Medic Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.
  • Baudin E; Department of Nuclear Medicine and Endocrine Tumors, Institut Gustave Roussy, Villejuif, France.
  • Demeure MJ; Translational Genomics Research Institute, Phoenix, AZ, USA.
  • Gilbert J; Vanderbilt School of Medicine, Nashville, TN, USA.
  • Haak H; Department of Internal Medicine, Máxima Medical Centre, Eindhoven, Netherlands; Department of Internal Medicine, Maastricht University Medical Centre, Maastricht, Netherlands; Maastricht University, Department of Health Services Research, and CAPHRI School for Public Health and Primary Care, Maastri
  • Kroiss M; Comprehensive Cancer Center Mainfranken, University of Würzburg, Würzburg, Germany.
  • Quinn DI; Univeristy of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
  • Hesseltine E; Endocrine Oncology Program-Comprehensive Cancer Center, University of Michigan Health System, Ann Arbor, MI, USA.
  • Ronchi CL; Central Laboratory, Research Unit, University Hospital Würzburg, Würzburg, Germany.
  • Terzolo M; Univerita degli Studi di Torino, Orbassano, Turin, Italy.
  • Choueiri TK; Dana-Farber Cancer Institute, Boston, MA, USA.
  • Poondru S; Astellas Pharma Global Development, Northbrook, IL, USA.
  • Fleege T; Astellas Pharma Global Development, Northbrook, IL, USA.
  • Rorig R; Astellas Pharma Global Development, Northbrook, IL, USA.
  • Chen J; Astellas Pharma Global Development, Northbrook, IL, USA.
  • Stephens AW; Piramal Imaging, Berlin, Germany.
  • Worden F; Endocrine Oncology Program-Comprehensive Cancer Center, University of Michigan Health System, Ann Arbor, MI, USA.
  • Hammer GD; Endocrine Oncology Program-Comprehensive Cancer Center, University of Michigan Health System, Ann Arbor, MI, USA. Electronic address: ghammer@umich.edu.
Lancet Oncol ; 16(4): 426-35, 2015 Apr.
Article en En | MEDLINE | ID: mdl-25795408
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Pirazinas / Carcinoma Corticosuprarrenal / Imidazoles / Metástasis de la Neoplasia Tipo de estudio: Clinical_trials / Guideline Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Año: 2015 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Pirazinas / Carcinoma Corticosuprarrenal / Imidazoles / Metástasis de la Neoplasia Tipo de estudio: Clinical_trials / Guideline Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Año: 2015 Tipo del documento: Article